Active substance expiry dates postponed whilst the renewal evaluation is completed in the EU. For reasons beyond the control of the applicants, the approvals of the active substance/product type combinations listed were likely to expire before a decision could be taken on their renewal under the EU Biocidal Products Regulation (EU BPR). To allow sufficient time for the renewal evaluation to be completed, a decision has been taken to postpone the expiry dates of the following approvals. This affects NI: From 30 June 2025 to 31 January 2026 Aluminium phosphide releasing phosphine (CAS 20859-73-8 EC 244-088-0) in product type 20 From 30 June 2025 to 31 December 2027 3-phenoxybenzyl-2-(4-ethoxyphenyl)-2-methylpropyl ether (etofenprox) (CAS 80844-07-1 EC 407-980-2) in product type 18 Copper sulphate pentahydrate (CAS 7758-99-8 EC 231-847-6) in product type 2 Benzoic acid (CAS 65-85-0 EC 200-618-2) in product types 3 and 4 3-iodo-2-propynylbutylcarbamate (IPBC) (CAS 55406-53-6 EC 259-627-5) in product type 6 If you want to supply new biocidal products containing these active substances, you can still apply for EU BPR product authorisation. New products (including new trade names) must not be supplied in NI until product authorisation is granted. HSE will provide separate updates on the renewal decisions when relevant. Biocidal products must be phased off the NI market. The active substance/product type combination listed is due to expire under the EU BPR on the following date. This affects NI: 31 October 2025 Synthetic amorphous silicon dioxide (nano) (CAS 112926-00-8 EC 231-545-4) in product type 18 Once the approval expires, the active substance will no longer be able to be used in biocidal products of the relevant product type in NI. In addition articles treated with such products will no longer be able to be placed on the market in NI. If you hold an affected EU BPR product authorisation or Control of Pesticides Regulations (COPR) product approval, we will contact you about cancelling or revoking your authorisation or approval. You will have an opportunity to submit comments or additional information and we will take account of these when finalising our decision. If you are aware of any disproportionate negative impacts that are likely to arise from the expiry of the active substance/product type combination listed, please contact us. |